| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10003345 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10021862 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10026352 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10041825 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10050222 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10052819 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10058988 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10058990 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10058987 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
| TVIS10058992 | HBV | ENSG00000156110.15 | protein_coding | ADK | No | No | 132 | P55263 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADK |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0003540 |
| UniProt ID | P55263 |
| Regulation Type | product of |
| PubMed IDs | 18560757; 17065073 |
| Citations | Park J, Gupta RS: Adenosine kinase and ribokinase--the RK family of proteins. Cell Mol Life Sci. 2008 Sep;65(18):2875-96. doi: 10.1007/s00018-008-8123-1.@@Leoncini R, Vannoni D, Santoro A, Giglioni S, Carli R, Marinello E: Adenosine kinase from rat liver: new biochemical properties. Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1107-12. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
